Figure 2.

Serum antibody levels were measured at multiple nodes of disease change for three of the patients at our center. MN1 patient (PLA2R- and NELL-1-positive) achieved remission after treatment, but relapsed 46 months later. His serum anti-PLA2R antibody titers were consistent with changes in urine protein, but his serum anti-NELL-1 antibody remained negative throughout the disease course (A); MN2 patient (PLA2R- and NELL-1-positive) achieved complete remission after treatment and there was no recurrence thereafter. His serum anti-PLA2R antibody titers continued to be 0R/ml and serum anti-NELL-1 antibodies continued to be negative (B); MN4 patient (PLA2R- and THSD7A-positive) did not improve after 4 months of treatment, with a slight decrease in serum anti-PLA2R antibody titers and continuous negative serum anti-THSD7A antibodies (C).